Recent advances in the understanding of the mechanisms of neovascularization and the identification of potent angiogenic growth factors have led to the development of therapeutic angiogenesis for treatment of severe ischemic heart disease. Current clinical studies on therapeutic myocardial angiogenesis generally involved the delivery of recombinant protein or gene of the angiogenic growth factors using various different approaches. Although the initial clinical results are encouraging, the potential side effects of these potent angiogenic growth factors remain a major concern. Large-scale, randomized and placebo control studies will be required to demonstrate the clinical benefit of this novel therapeutic treatment of ischemic heart disease.
Hung-Fat Tse, Chu-Pak Lau, Update on Therapeutic Myocardial Angiogenesis Journal of the Hong Kong College of Cardiology 2002;10(2) https://doi.org/10.55503/2790-6744.1142
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.